In this open-label, dose rising, Phase 2a trial with an expanded cohort at the dose of NanoPac® (Sterile Nanoparticulate Paclitaxel) determined to have the best tolerability and safety profile, subjects with mucinous cystic pancreatic neoplasms will receive intracystic NanoPac® via endoscopic ultrasound-guided fine needle injection (EUS-FNI). The study will include a dose escalation phase and a dose confirmation phase.